Genetic Basis of Cancer of the Kidney

Studies during the past two decades have shown that kidney cancer is not a single disease; it is made up of a number of different types of cancer that occur in this organ. Clear cell renal carcinoma is characterized by mutation of the VHL gene. The VHL gene product forms a heterotrimeric complex with elongin C, elongin B, and Cul-2 to target hypoxia-inducible factors 1 and 2α for ubiquitin-mediated degradation. VHL−/− clear cell renal carcinoma overexpresses epidermal growth factor receptor and transforming growth factor α. Both hypoxia-inducible factor 1α and the epidermal growth factor receptor are potential therapeutic targets in clear cell renal carcinoma. Studies of the hereditary form of renal cell carcinoma (RCC) associated with hereditary papillary renal carcinoma (HPRC) determined that the c-Met proto-oncogene on chromosome 7 is the gene for HPRC and for a number of sporadic papillary RCCs. The HPRC c-Met mutations are activating mutations in the tyrosine kinase domain of the gene. The gene for a new form of hereditary RCC (Birt Hogg Dubé syndrome) associated with cutaneous tumors, lung cysts, and colon polyps or cancer has recently been identified. Studies are currently under way to determine what type of gene BHD is and how damage to this gene leads to kidney cancer. Individuals affected with hereditary leiomyomatosis renal cell carcinoma are at risk for the development of cutaneous leiomyomas, uterine leiomyomas (fibroids), and type 2 papillary RCC. The HLRC gene has been found to be the Krebs cycle enzyme, fumarate hydratase. Studies are under way to understand the downstream pathway of this cancer gene.

[1]  W. Kaelin.  The Von Hippel-Lindau Tumor Suppressor Gene and Kidney Cancer , 2004, Clinical Cancer Research.

[2]  C. Birchmeier,et al.  Developmental roles of HGF/SF and its receptor, the c-Met tyrosine kinase. , 1998, Trends in cell biology.

[3]  W. J. Dubé,et al.  Hereditary multiple fibrofolliculomas with trichodiscomas and acrochordons. , 1977, Archives of dermatology.

[4]  M. Tyers,et al.  VHL: a very hip ligase. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[5]  Germline and somatic mutations in the tyrosine kinase domain of the MET proto-oncogene in papillary renal carcinomas , 1997, Nature Genetics.

[6]  R. Conaway,et al.  Activation of HIF1alpha ubiquitination by a reconstituted von Hippel-Lindau (VHL) tumor suppressor complex. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[7]  P. Choyke,et al.  Hereditary and sporadic papillary renal carcinomas with c-met mutations share a distinct morphological phenotype. , 1999, The American journal of pathology.

[8]  L. Neckers,et al.  Hsp90 Regulates a von Hippel Lindau-independent Hypoxia-inducible Factor-1α-degradative Pathway* , 2002, The Journal of Biological Chemistry.

[9]  W. Linehan,et al.  Novel mutations of the MET proto-oncogene in papillary renal carcinomas , 1999, Oncogene.

[10]  V. Devita,et al.  Cancer : Principles and Practice of Oncology , 1982 .

[11]  G. Michalopoulos,et al.  Liver Regeneration , 1997, Science.

[12]  S. Richard,et al.  Inactivation of BHD in sporadic renal tumors. , 2003, Cancer research.

[13]  D. Duan,et al.  Inhibition of transcription elongation by the VHL tumor suppressor protein , 1995, Science.

[14]  J. Gnarra,et al.  Identification of the von Hippel-Lindau disease tumor suppressor gene. , 1993, Science.

[15]  Tony Pawson,et al.  Mammalian Grb2 Regulates Multiple Steps in Embryonic Development and Malignant Transformation , 1998, Cell.

[16]  E. Mazeman.  [CANCER OF THE KIDNEY]. , 1963, Lille chirurgical.

[17]  P. Choyke,et al.  Original Articles: Kidney Cancer , 1995 .

[18]  Z. Yao,et al.  Potent Blockade of Hepatocyte Growth Factor-stimulated Cell Motility, Matrix Invasion and Branching Morphogenesis by Antagonists of Grb2 Src Homology 2 Domain Interactions* , 2001, The Journal of Biological Chemistry.

[19]  M. Maqueo Topete,et al.  [Renal carcinoma]. , 1959, Revista de investigacion clinica; organo del Hospital de Enfermedades de la Nutricion.

[20]  W. Linehan,et al.  Allelic deletions of the VHL gene detected in multiple microscopic clear cell renal lesions in von Hippel-Lindau disease patients. , 1996, The American journal of pathology.

[21]  R. Klausner,et al.  The von Hippel-Lindau tumor-suppressor gene product forms a stable complex with human CUL-2, a member of the Cdc53 family of proteins. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[22]  K. Kinzler,et al.  The Genetic Basis of Human Cancer , 1997 .

[23]  Richard D Klausner,et al.  The contribution of VHL substrate binding and HIF1-alpha to the phenotype of VHL loss in renal cell carcinoma. , 2002, Cancer cell.

[24]  G. V. Vande Woude,et al.  HGF/SF‐met signaling in the control of branching morphogenesis and invasion , 2003, Journal of cellular biochemistry.

[25]  L. Neckers,et al.  Hsp90 regulates a von Hippel Lindau-independent hypoxia-inducible factor-1 alpha-degradative pathway. , 2002, The Journal of biological chemistry.

[26]  Tsutomu Ohta,et al.  Overexpression of KIT in chromophobe renal cell carcinoma , 2003, Oncogene.

[27]  Mirna Lechpammer,et al.  Inhibition of HIF is necessary for tumor suppression by the von Hippel-Lindau protein. , 2002, Cancer cell.

[28]  Maria Merino,et al.  Mutations in a novel gene lead to kidney tumors, lung wall defects, and benign tumors of the hair follicle in patients with the Birt-Hogg-Dubé syndrome. , 2002, Cancer cell.

[29]  W. Linehan,et al.  Characterization of the renal pathology of a familial form of renal cell carcinoma associated with von Hippel-Lindau disease: clinical and molecular genetic implications. , 1995, The Journal of urology.

[30]  Y. Nakamura,et al.  Specific genetic change in tumors associated with von Hippel-Lindau disease. , 1989, Journal of the National Cancer Institute.

[31]  H. Kwon,et al.  Reduction of hypoxia-induced transcription through the repression of hypoxia-inducible factor-1alpha/aryl hydrocarbon receptor nuclear translocator DNA binding by the 90-kDa heat-shock protein inhibitor radicicol. , 2002, Molecular pharmacology.

[32]  W Marston Linehan,et al.  Genetic Basis of Cancer of the Kidney , 2006 .

[33]  W. Linehan,et al.  Renal Tumors in the Birt-Hogg-Dubé Syndrome , 2002, The American journal of surgical pathology.

[34]  P. Choyke,et al.  Hereditary papillary renal cell carcinoma. , 1994, The Journal of urology.

[35]  W. Krek.  VHL takes HIF’s breath away , 2000, Nature Cell Biology.

[36]  Tim Eisen,et al.  Kinase Inhibition with BAY 43–9006 in Renal Cell Carcinoma , 2004, Clinical Cancer Research.

[37]  D. Scudiero,et al.  Identification of small molecule inhibitors of hypoxia-inducible factor 1 transcriptional activation pathway. , 2002, Cancer research.

[38]  P. Choyke,et al.  Risk of renal and colonic neoplasms and spontaneous pneumothorax in the Birt-Hogg-Dubé syndrome. , 2002, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.

[39]  Y. Pommier,et al.  Topoisomerase I-Mediated Inhibition of Hypoxia-Inducible Factor 1 , 2004, Cancer Research.

[40]  L. Aaltonen,et al.  Inherited susceptibility to uterine leiomyomas and renal cell cancer , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[41]  P. Comoglio,et al.  Regulation of scatter factor/hepatocyte growth factor responses by Ras, Rac, and Rho in MDCK cells , 1995, Molecular and cellular biology.

[42]  G. Fontanini,et al.  Antitumor effects of ZD6474, a small molecule vascular endothelial growth factor receptor tyrosine kinase inhibitor, with additional activity against epidermal growth factor receptor tyrosine kinase. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

[43]  A. Potti,et al.  Tyrosine Kinase Inhibitors in Renal Cell Carcinoma , 2004, Clinical Cancer Research.

[44]  C. Pan,et al.  A distinct expression pattern and point mutation of c-KIT in papillary renal cell carcinomas , 2004, Modern Pathology.

[45]  R. Johnson,et al.  Two HIFs may be better than one. , 2002, Cancer cell.

[46]  B. Zbar,et al.  Birt-Hogg-Dubé syndrome: a novel marker of kidney neoplasia. , 1999, Archives of dermatology.

[47]  M. Gassmann,et al.  Functional interference between hypoxia and dioxin signal transduction pathways: competition for recruitment of the Arnt transcription factor , 1996, Molecular and cellular biology.

[48]  P. Choyke,et al.  Mutations in the fumarate hydratase gene cause hereditary leiomyomatosis and renal cell cancer in families in North America. , 2003, American journal of human genetics.

[49]  A. Paetau,et al.  Germline mutations in FH predispose to dominantly inherited uterine fibroids, skin leiomyomata and papillary renal cell cancer , 2002, Nature Genetics.

[50]  J. Brooks,et al.  Mutations of the VHL tumour suppressor gene in renal carcinoma , 1994, Nature Genetics.

[51]  Pierre Hubert,et al.  Tyrosine kinase receptors as attractive targets of cancer therapy. , 2004, Critical reviews in oncology/hematology.

[52]  M. Ivan,et al.  Ubiquitination of hypoxia-inducible factor requires direct binding to the β-domain of the von Hippel–Lindau protein , 2000, Nature Cell Biology.

[53]  W. Linehan,et al.  Prevalence of microscopic lesions in grossly normal renal parenchyma from patients with von Hippel-Lindau disease, sporadic renal cell carcinoma and no renal disease: clinical implications. , 1995, The Journal of urology.

[54]  W. Linehan,et al.  Identification of the von Hippel-Lindau (VHL) gene. Its role in renal cancer. , 1995, JAMA.

[55]  L. Schmidt,et al.  Activating mutations for the met tyrosine kinase receptor in human cancer. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[56]  D. Mottet,et al.  Hypoxia‐induced activation of HIF‐1: role of HIF‐1α‐Hsp90 interaction , 1999 .

[57]  P. Choyke,et al.  Localization of the von Hippel-Lindau disease gene to a small region of chromosome 3. , 1990, Genomics.

[58]  W. Linehan,et al.  Re: Hereditary Papillary Renal Cell Carcinoma; Re Hereditary Papillary Renal Cell Carcinoma Clinical Studies in 10 Families , 1996 .

[59]  M. GreyJde.  [Cancer of the kidney]. , 1950, L' Hopital.

[60]  J. Herman,et al.  Silencing of the VHL tumor-suppressor gene by DNA methylation in renal carcinoma. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[61]  D. Mottet,et al.  Hypoxia-induced activation of HIF-1: role of HIF-1alpha-Hsp90 interaction. , 1999, FEBS letters.